Obesity / Overweight – Epidemiology – Asia-Pacific

Clarivate Epidemiology’s coverage of obesity / overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of obesity / overweight for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s obesity / overweight forecast will answer the following questions:

• Of all people with obesity / overweight, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of obesity / overweight over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 11 obesity/overweight patient populations, as follows:

• Diagnosed prevalent cases of obesity / overweight.
• Undiagnosed prevalent cases of obesity / overweight.
• Total prevalent cases of obesity.
• Total prevalent cases of class I obesity.
• Total prevalent cases of class II obesity.
• Total prevalent cases of class III obesity.
• Total prevalent cases of overweight.
• Total obesity prevalent cases after effective usage of GLP-1 RAs.
• Drug-treatable prevalent cases of overweight.
• Diagnosed drug-treated prevalent cases of obesity.
• Diagnosed non-drug-treated prevalent cases of obesity.

Note: Coverage may vary by country.